Cogent joins OnKure with a clinical-stage H1047Rm-specific PI3Kα inhibitor.
ApexOnco Front Page
Recent articles
The company’s latest phase 3 for its biparatopic ADC is in colorectal cancer.
And the company might one day follow Galapagos into decentralised manufacturing.
The group claims a seven-day vein-to-vein time is unique, and says why this matters.
Yet more data validate B7-H3, and put MediLink in the deal-making frame.
The company’s TARA-002 produces competitive results in BCG-unresponsive bladder cancer, albeit in just five patients.
The group’s cancer focus is a TROP2 ADC it reckons could have a safety and efficacy edge.
Gilead links up with Tubulis, while GSK taps BioNTech’s partner DualityBio.
